UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 33,025 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 2.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,544,802 shares of the company’s stock after selling 33,025 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.22% of ImmunityBio worth $5,747,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in IBRX. Algert Global LLC bought a new stake in shares of ImmunityBio during the second quarter worth approximately $86,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after acquiring an additional 4,545 shares during the period. Simplicity Wealth LLC boosted its stake in shares of ImmunityBio by 46.0% in the second quarter. Simplicity Wealth LLC now owns 15,806 shares of the company’s stock valued at $100,000 after buying an additional 4,983 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of ImmunityBio in the second quarter valued at approximately $105,000. Finally, Courier Capital LLC boosted its stake in shares of ImmunityBio by 50.0% in the third quarter. Courier Capital LLC now owns 30,000 shares of the company’s stock valued at $112,000 after buying an additional 10,000 shares during the period. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

NASDAQ IBRX opened at $4.64 on Wednesday. The business has a fifty day moving average price of $4.59 and a two-hundred day moving average price of $4.92. ImmunityBio, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $10.53. The stock has a market capitalization of $3.23 billion, a PE ratio of -5.04 and a beta of 0.86.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Piper Sandler cut their price target on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research note on Monday, August 19th. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of ImmunityBio in a research note on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.